Matthias Noack‐Rink

Statistics

Publications

Citations

145

H-Index

Active since

2015

Affiliations

UCB Pharma (Germany)(Current)

UCB Pharma (Belgium)

Matthias Noack‐Rink is an author at UCB Pharma (Germany) specializing in antiepileptic pharmacology, seizure management, and antiepileptic pharmacotherapy.

Publications per year

2015–2017

Publications

Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study

Bernd Pohlmann‐Eden, Anthony G Marson, Matthias Noack‐Rink et al. · BMC Neurology · 2016 · 65 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial‐onset seizures in daily clinical practice: The <scp>VITOBA</scp> study

Uwe Runge, Stephan Arnold, Christian Brandt et al. · Epilepsia · 2015 · 60 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Health care cost associated with the use of enzyme-inducing and non-enzyme–active antiepileptic drugs in the UK: a long-term retrospective matched cohort study

Simon Borghs, S Thieffry, Matthias Noack‐Rink et al. · BMC Neurology · 2017 · 20 citations · Full text

Medicine, Pharmacoeconomics, Pharmacology +17

1–3 of 3